MCA logo



Upadacitinib (Rinvoq): Once-Daily Oral Treatment for Rheumatoid Arthritis (RA)

upadacitinib rinvoq treatment for rheumatoid arthritis (RA)

Disease Burden and Current Treatment Landscape
In June 2020, upadacitinib hemihydrate (Rinvoq; AbbVie), an oral reversible JAK1 selective inhibitor received local regulatory approval for use in ‘moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: